Solenic Medical

Executive Summary

Solenic Medical is a privately held medical device and digital health company pioneering a non-invasive platform for treating infected metallic implants. Founded in 2019 and headquartered in San Francisco, the company leverages patented alternating magnetic field (AMF) technology to eradicate biofilms on implant surfaces, addressing a common and costly surgical complication. By eliminating the need for risky revision surgeries, Solenic's approach has the potential to transform standard of care for implant-related infections, a major unmet need affecting hundreds of thousands of patients annually. The company's technology is still in preclinical or early clinical stages, with no disclosed funding rounds or regulatory approvals to date, but its innovative mechanism and strong value proposition position it as an attractive opportunity in the medtech space. Solenic's success will hinge on demonstrating safety and efficacy in human trials, securing regulatory clearances, and establishing commercial partnerships. While the company faces typical early-stage risks, the large addressable market and compelling clinical need support a favorable long-term outlook if technical milestones are achieved.

Upcoming Catalysts (preview)

• Q3 2026Initiation of pivotal clinical trial for infected orthopedic implants40% success
• Q2 2026FDA breakthrough device designation60% success
• Q1 2026Publication of preclinical in vivo efficacy data in peer-reviewed journal70% success